Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Published in: Journal of Neurology 2/2018

01-02-2018 | Original Communication

Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim–Chester disease

Authors: Luisa Chiapparini, Giulio Cavalli, Tiziana Langella, Anna Venerando, Giacomo De Luca, Sergio Raspante, Giorgio Marotta, Bianca Pollo, Giuseppe Lauria, Maria Giulia Cangi, Simonetta Gerevini, Andrea Botturi, Davide Pareyson, Lorenzo Dagna, Ettore Salsano

Published in: Journal of Neurology | Issue 2/2018

Login to get access

Abstract

Background

Leukoencephalopathies with prominent involvement of cerebellum and brainstem, henceforward called prominent infratentorial leukoencephalopathies (PILs), encompass a variety of inherited and acquired white matter diseases. Erdheim–Chester disease (ECD) is a rare non-Langerhans cell histiocytosis likely under-diagnosed as cause of adult PIL.

Methods

We reviewed the clinical and laboratory information of ten consecutive sporadic adult patients with PIL of unknown origin, who were investigated for ECD.

Results

There were seven males and three females; mean age at clinical onset was 49.6 years (range 38–59); cerebellar ataxia with or without other neurological symptoms was the only or the main clinical manifestation; diabetes insipidus was present in three individuals. Eight patients had white matter focal supratentorial abnormalities, in addition to the infratentorial white matter changes. Six out of eight patients had spinal cord lesions. Thoraco-abdominal CT showed periaortic sheathing in two patients, whole-body FDG-PET revealed increased glucose uptake in the long bones of the legs in five patients, brain FDG-PET showed overt infratentorial hypermetabolism in one patient. In eight patients, ECD was confirmed by bone scintigraphy, pathological data, or both. Two ECD patients treated with vemurafenib showed a marked improvement of neurological symptoms and brain MRI abnormalities at 1 year follow-up.

Conclusions

Symptoms of PIL can be the only clinical manifestation of ECD. Adult patients with PIL of unknown origin should undergo investigations aimed at unveiling ECD, including bone scintigraphy and whole-body FDG-PET. The early diagnosis allows starting disease-modifying therapies of an otherwise life-threatening disease.
Literature
1.
2.
Gass A, Filippi M, Grossman RI (2000) The contribution of MRI in the differential diagnosis of posterior fossa damage. J NeurolSci 172(Suppl 1):S43–S49
3.
Rovira À, Sastre-Garriga J, Auger C et al (2013) Idiopathic inflammatory demyelinating diseases of the brainstem. Semin Ultrasound CT MR 34:123–130CrossRefPubMed
4.
Akman-Demir G, Bahar S, Coban O et al (2003) Cranial MRI in Behçet’s disease: 134 examinations of 98 patients. Neuroradiology 45:851–859CrossRefPubMed
5.
Pittock SJ, Debruyne J, Krecke KN et al (2010) Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain 133:2626–2634CrossRefPubMed
6.
Tateishi U, Terae S, Ogata A et al (2001) MR imaging of the brain in lymphomatoidgranulomatosis. AJNR Am J Neuroradiol 22:1283–1290PubMed
7.
8.
9.
Singh TD, Fugate JE, Rabinstein AA (2014) Central pontine and extrapontine myelinolysis: a systematic review. Eur J Neurol 21:1443–1450CrossRefPubMed
10.
van der Knaap MS, Arts WF, Garbern JY et al (2008) Cerebellar leukoencephalopathy: most likely histiocytosis-related. Neurology 71:1361–1367CrossRefPubMed
11.
Diamond EL, Dagna L, Hyman DM et al (2014) Consensus guidelines for the diagnosis and clinical management of Erdheim–Chester disease. Blood 124:483–492CrossRefPubMedPubMedCentral
12.
Cavalli G, Guglielmi B, Berti A et al (2013) The multifaceted clinical presentations and manifestations of Erdheim–Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis 72:1691–1695CrossRefPubMed
13.
Salsano E, Savoiardo M, Nappini S et al (2008) Late-onset sporadic ataxia, pontine lesion, and retroperitoneal fibrosis: a case of Erdheim–Chester disease. Neurol Sci 29:263–267CrossRefPubMed
14.
Cangi MG, Biavasco R, Cavalli G et al (2015) BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim–Chester disease. Ann Rheum Dis 74:1596–1602CrossRefPubMed
15.
Cavalli G, Biavasco R, Borgiani B et al (2014) Oncogene-induced senescence as a new mechanism of disease: the paradigm of Erdheim–Chester disease. Front Immunol 5:281CrossRefPubMedPubMedCentral
16.
Arnaud L, Hervier B, Néel A et al (2011) CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim–Chester disease: a multicenter survival analysis of 53 patients. Blood 117:2778–2782CrossRefPubMed
17.
18.
Haroche J, Cohen-Aubart F, Emile JF et al (2015) Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim–Chester disease. J Clin Oncol 33:411–418CrossRefPubMed
19.
López RF, Báñez IA, Robles MB et al (2017) 18F-FDG PET/CT in Erdheim–Chester disease. Eur J Nucl Med Mol Imaging 44:1247–1248CrossRefPubMed
20.
Ayrignac X, Boutiere C, Carra-Dalliere C et al (2016) Posterior fossa involvement in the diagnosis of adult-onset inherited leukoencephalopathies. J Neurol 263:2361–2368CrossRefPubMed
21.
Campochiaro C, Tomelleri A, Cavalli G et al (2015) Erdheim–Chester disease. Eur J Intern Med 26:223–229CrossRefPubMed
22.
Lachenal F, Cotton F, Desmurs-Clavel H et al (2006) Neurological manifestations and neuroradiological presentation of Erdheim–Chester disease: report of 6 cases and systematic review of the literature. J Neurol 253:1267–1277CrossRefPubMed
23.
Bianco F, Iacovelli E, Tinelli E et al (2009) Characteristic brain MRI appearance of Erdheim–Chester disease. Neurology 73:2120–2122CrossRefPubMed
24.
Adle-Biassette H, Chetritt J, Bergemer-Fouquet AM et al (1997) Pathology of the central nervous system in Chester-Erdheim disease: report of three cases. J Neuropathol Exp Neurol 56:1207–1216CrossRefPubMed
25.
Diamond EL, Hatzoglou V, Patel S et al (2016) Diffuse reduction of cerebral grey matter volumes in Erdheim–Chester disease. Orphanet J Rare Dis 11:109CrossRefPubMedPubMedCentral
26.
Tien R, Kucharczyk J, Kucharczyk W (1991) MR imaging of the brain in patients with diabetes insipidus. AJNR Am J Neuroradiol 12:533–542PubMed
27.
Prosch H, Grois N, Bökkerink J et al (2006) Central diabetes insipidus: is it Langerhans cell histiocytosis of the pituitary stalk? A diagnostic pitfall. Pediatr Blood Cancer 46:363–366CrossRefPubMed
28.
Drier A, Haroche J, Savatovsky J et al (2010) Cerebral, facial, and orbital involvement in Erdheim–Chester disease: CT and MR imaging findings. Radiology 255:586–594CrossRefPubMed
29.
Grois N, Prayer D, Prosch H et al (2005) Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain 128:829–838CrossRefPubMed
30.
Ferrero E, Corti A, Haroche J et al (2016) Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim–Chester disease. Oncoimmunology 5:e1181244CrossRefPubMedPubMedCentral
31.
Bargagli E, Maggiorelli C, Rottoli P (2008) Human chitotriosidase: a potential new marker of sarcoidosis severity. Respiration 76:234–238CrossRefPubMed
32.
Mossetti G, Rendina D, Numis FG et al (2003) Biochemical markers of bone turnover, serum levels of interleukin-6/interleukin-6 soluble receptor and bisphosphonate treatment in Erdheim–Chester disease. Clin Exp Rheumatol 21:232–236PubMed
33.
34.
Sedrak P, Ketonen L, Hou P et al (2011) Erdheim–Chester disease of the central nervous system: new manifestations of a rare disease. AJNR Am J Neuroradiol 32:2126–2131CrossRefPubMed
35.
Shamburek RD, Brewer HB Jr, Gochuico BR (2001) Erdheim–Chester disease: a rare multisystem histiocytic disorder associated with interstitial lung disease. Am J Med Sci 321:66–75CrossRefPubMed
36.
Birnbaum DC, Shields D, Lippe B et al (1989) Idiopathic central diabetes insipidus followed by progressive spastic cerebral ataxia. Report of four cases. Arch Neurol 46:1001–1003CrossRefPubMed
Metadata
Title
Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim–Chester disease
Authors
Luisa Chiapparini
Giulio Cavalli
Tiziana Langella
Anna Venerando
Giacomo De Luca
Sergio Raspante
Giorgio Marotta
Bianca Pollo
Giuseppe Lauria
Maria Giulia Cangi
Simonetta Gerevini
Andrea Botturi
Davide Pareyson
Lorenzo Dagna
Ettore Salsano
Publication date
01-02-2018
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 2/2018
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-017-8692-8

Other articles of this Issue 2/2018

Journal of Neurology 2/2018 Go to the issue

Original Communication

Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?

Original Communication

Vestibular impairment in chronic inflammatory demyelinating polyneuropathy

Original Communication

Efficacy and safety of rotigotine in elderly patients with Parkinson’s disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials

Pioneers in Neurology

Eric Heinz Lenneberg (1921–1975)

Original Communication

Altered effective connectivity contributes to micrographia in patients with Parkinson’s disease and freezing of gait

Original Communication

INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin